Who are Transdermal Scopolamine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Northera, Vesicare, Evoxac, Detrol, Atrovent, Provocholine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/transdermal-scopolamine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Transdermal Scopolamine — Competitive Intelligence Brief

Transdermal Scopolamine (Transdermal Scopolamine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic agent. Area: Gastroenterology / Neurology.

marketed Anticholinergic agent Muscarinic acetylcholine receptor (M1) Gastroenterology / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Transdermal Scopolamine (Transdermal Scopolamine) — Repurposed Therapeutics, Inc.. Transdermal scopolamine blocks muscarinic acetylcholine receptors to reduce motion sickness and nausea by decreasing vestibular sensitivity and gastric motility.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Transdermal Scopolamine TARGET	Transdermal Scopolamine	Repurposed Therapeutics, Inc.	marketed	Anticholinergic agent	Muscarinic acetylcholine receptor (M1)
Northera	DROXIDOPA	Lundbeck Na Ltd	marketed	Catecholamine	Muscarinic acetylcholine receptor M1	2014-01-01
Vesicare	SOLIFENACIN	Astellas Pharma	marketed	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M1	2004-01-01
Evoxac	CEVIMELINE	Cosette	marketed	Cholinergic Receptor Agonist	Muscarinic acetylcholine receptor M1	2000-01-01
Detrol	TOLTERODINE	Upjohn	marketed	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M1	1998-01-01
Atrovent	IPRATROPIUM		marketed	Anticholinergic	Muscarinic acetylcholine receptor M1	1986-01-01
Provocholine	METHACHOLINE	Methapharm	marketed	Cholinergic Receptor Agonist	Muscarinic acetylcholine receptor M1	1986-01-01

Recent regulatory actions (last 90 days)

2026-02-23 — Atrovent · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic agent class)

Repurposed Therapeutics, Inc. · 2 drugs in this class
University of Iowa · 2 drugs in this class
Alza Corporation, DE, USA · 2 drugs in this class
Janssen-Cilag Ltd.,Thailand · 1 drug in this class
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
Rutgers, The State University of New Jersey · 1 drug in this class
Stony Brook University · 1 drug in this class
Toronto Rehabilitation Institute · 1 drug in this class
US Department of Veterans Affairs · 1 drug in this class
University of California, Davis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Transdermal Scopolamine — Competitive Intelligence Brief. https://druglandscape.com/ci/transdermal-scopolamine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab